Skip to main content
. 2017 Aug 3;16:311. doi: 10.1186/s12936-017-1963-0

Table 1.

Description of the data set in terms of studies per treatment and the sample sizes, on day 28

Treatments Studies per treatment arm Studies tested the trt with AL Total sample size Nbr of ACPR % of ACPR
AL 63 12,981 11,426 88
AQSP 12 7 2681 1731 64.56
ASAQ 42 31 8254 7402 89.6
ASAQCPH 1 1 54 47 87.03
ASATPG 1 0a 100 95 95
ASCD 4 4 1591 1326 83.3
ASMQ 6 5 843 800 94.89
ASNAPH 2 2 147 144 97.95
ASPY 2 2 1204 1105 91.77
ASSMP 4 3 1545 1461 94.5
ASSP 11 3 1752 1593 91
DHAP 22 18 6182 4969 80.3
DHAPT 1 1 212 204 96.2

Data were extracted for all studies. The combination AL was the most frequently evaluated drug combination within the data. Few studies tested novel combinations. There was no study comparing ASATPG directly to AL

Nbr number, trt treatment, ACPR adequate clinical and parasitological response corrected by PCR